Completion of ACTIV-2 Study

NIAID正在赞助一项新冠肺炎新疗法的临床研究，这是加速新冠肺炎治疗干预和疫苗(ACTV)的临床研究之一。拥有现有的临床试验基础设施和多个支持合同，以提供与临床试验支持、监管支持和药房支持相关的服务， NIAID是新冠肺炎临床试验的赞助商，该试验的标题是：A5401：适用于 新冠肺炎门诊患者(适应新冠状病毒感染)“也被称为ACTV-2。ACTV-2的目的是评估多种研究药物的安全性和有效性，这些药物旨在改变宿主对SARS-CoV-2感染的免疫反应，或直接加强病毒控制，以限制疾病的进展。

NIAID is sponsoring a clinical research study on novel therapeutics for COVID-19, which is one of the clinical studies for Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV). With an existing clinical trial infrastructure and multiple support contracts to provide services related to clinical trials support, regulatory support and pharmacy support, NIAID serves as the sponsor for the COVID-19 clinical trial entitled “A5401: Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID)” also known as ACTIV-2. The objective of ACTIV-2 is to evaluate the safety and efficacy of multiple investigational agents aimed at modifying the host immune response to SARS-CoV-2 infection, or directly enhancing viral control in order to limit disease progression.